Open Nav

NOBIO LTD.

  • Yoram Ashery, NOBIO LTD.

Round B financing

  • Date:Thursday, October 18
  • Time:11:15 AM - 11:30 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Nobio aims to prevent contamination and infection virtually everywhere with a novel, universal antimicrobial technology. Infectious disease account for 15% of global deaths. Treating hospital acquired infections in the US alone costs over $30 billion a year. Nobio’s technology turns commonly used materials into antimicrobial permanently, using proprietary nanoparticles. 22 published studies, including 2 clinical trials, showed strong, long-lasting effect against a broad spectrum of bacteria. First market entry will be in dentistry in 2019, with the first antimicrobial dental restoratives ($1.4B market), for preventing secondary caries, the world’s most common chronic infection. Pipeline includes cements, sealants and implant coatings. Promising animal studies in medical applications (wound-dressing, implants and catheters) as the next application area. In licensing discussions with industry leaders in the above categories, as well as in industrial, infrastructure and consumer products.
  • Company Website:www.nobio.com
  • Company HQ City:Petach Tikva
  • Company HQ Country:Israel
  • CEO/Top Company Official:Yoram Ashery
  • Year Founded:2015
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :Nobio Antimicrobial Particles
  • Development Phase of Primary Product:NDA Preparation / In Review
  • Additional Information/Comments:Nobio’s nanoparticles can be embedded in the product material during production or applied as coating. They’re insoluble, act only by contact, therefore effective indefinitely, unlike any existing antimicrobial technology. Their effect is very strong: 1% concentration reduces bacteria count by 7 logs (as much as can be measured). It will prevent biofilm formation, which is associated with up to 80% of human infections. Bacteria in biofilm are x1000 resistant to disinfectants, the immune system and antibiotics. Preventing biofilm can therefore prevent most infections. Implants, like breast, cardiac, orthopedic or mesh, have 2%-4% or more chance of infection, which may require removal and may also be fatal. Contamination is a challenge not only in medicine and dentistry, but in almost all areas of life: food or drug manufacturing, air and water systems, textiles, packages, house-hold products for babies or personal hygiene and many more, all are potential uses for Nobio’s technology.
  • Previous and Current Investors:aMoon Fund
  • Size of Last Investment Round:$3,600,000
  • Total Amount Raised to Date, In All Rounds:$6,600,000
Speakers
Yoram Ashery
NOBIO LTD.
Back